- Home
- REGN vs MDT Comparison
REGN vs MDT Comparison
Compare REGN & MDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- MDT
- Stock Information
- Founded
- REGN 1988
- MDT 1949
- Country
- REGN United States
- MDT Ireland
- Employees
- REGN N/A
- MDT N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- MDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- REGN Health Care
- MDT Health Care
- Exchange
- REGN Nasdaq
- MDT Nasdaq
- Market Cap
- REGN 110.0B
- MDT 116.9B
- IPO Year
- REGN 1991
- MDT N/A
- Fundamental
- Price
- REGN $738.00
- MDT $86.21
- Analyst Decision
- REGN Buy
- MDT Hold
- Analyst Count
- REGN 24
- MDT 17
- Target Price
- REGN $1,110.63
- MDT $93.94
- AVG Volume (30 Days)
- REGN 887.5K
- MDT 6.8M
- Earning Date
- REGN 10-31-2024
- MDT 11-19-2024
- Dividend Yield
- REGN N/A
- MDT 3.25%
- EPS Growth
- REGN 15.31
- MDT 6.39
- EPS
- REGN 40.43
- MDT 3.27
- Revenue
- REGN $13,847,100,000.00
- MDT $32,996,000,000.00
- Revenue This Year
- REGN $10.13
- MDT $4.92
- Revenue Next Year
- REGN $4.00
- MDT $4.77
- P/E Ratio
- REGN $18.25
- MDT $26.39
- Revenue Growth
- REGN 5.72
- MDT 3.25
- 52 Week Low
- REGN $735.95
- MDT $75.96
- 52 Week High
- REGN $1,211.20
- MDT $92.68
- Technical
- Relative Strength Index (RSI)
- REGN 13.13
- MDT 42.79
- Support Level
- REGN $735.95
- MDT $83.55
- Resistance Level
- REGN $757.56
- MDT $88.72
- Average True Range (ATR)
- REGN 18.56
- MDT 1.63
- MACD
- REGN -1.24
- MDT -0.37
- Stochastic Oscillator
- REGN 1.89
- MDT 31.37
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About MDT Medtronic plc.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.